%0 Journal Article
%A Ramos-Rincon, Jose Manuel
%A Perez-Belmonte, Luis M
%A Carrasco-Sanchez, Francisco Javier
%A Jansen-Chaparro, Sergio
%A De-Sousa-Baena, Mercedes
%A Bueno-Fonseca, Jose
%A Perez-Aguilar, Maria
%A Arevalo-Cañas, Coral
%A Bacete-Cebrian, Marta
%A Mendez-Bailon, Manuel
%A Fiteni-Mera, Isabel
%A Gonzalez-Garcia, Andres
%A Navarro-Romero, Francisco
%A Tuñon-de-Almeida, Carlota
%A Muñiz-Nicolas, Gemma
%A Gonzalez-Noya, Amara
%A Hernandez-Milian, Almudena
%A Garcia-Garcia, Gema Maria
%A Alcala-Pedrajas, Jose Nicolas
%A Herrero-Garcia, Virginia
%A Corral-Gudino, Luis
%A Comas Casanova, Pere
%A Meijide-Miguez, Hector
%A Casas-Rojo, Jose Manuel
%A Gomez-Huelgas, Ricardo
%T Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19.
%D 2021
%U http://hdl.handle.net/10668/17741
%X The effects of cardiometabolic drugs on the prognosis of diabetic patients with COVID-19, especially very old patients, are not well known. This work was aimed to analyze the association between preadmission cardiometabolic therapy (antidiabetic, antiaggregant, antihypertensive, and lipid-lowering drugs) and in-hospital mortality among patients ≥80 years with type 2 diabetes mellitus (T2DM) hospitalized for COVID-19. We conducted a nationwide, multicenter, observational study in patients ≥80 years with T2DM hospitalized for COVID-19 between March 1 and May 29, 2020. The primary outcome measure was in-hospital mortality. A multivariate logistic regression analysis was performed to assess the association between preadmission cardiometabolic therapy and in-hospital mortality. Of the 2 763 patients ≥80 years old hospitalized due to COVID-19, 790 (28.6%) had T2DM. Of these patients, 385 (48.7%) died during admission. On the multivariate analysis, the use of dipeptidyl peptidase-4 inhibitors (adjusted odds ratio [AOR] 0.502, 95% confidence interval [CI]: 0.309-0.815, p = .005) and angiotensin receptor blockers (AOR 0.454, 95% CI: 0.274-0.759, p = .003) were independent protectors against in-hospital mortality, whereas the use of acetylsalicylic acid was associated with higher in-hospital mortality (AOR 1.761, 95% CI: 1.092-2.842, p = .020). Other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins showed neutral association with in-hospital mortality. We found important differences between cardiometabolic drugs and in-hospital mortality in older patients with T2DM hospitalized for COVID-19. Preadmission treatment with dipeptidyl peptidase-4 inhibitors and angiotensin receptor blockers could reduce in-hospital mortality; other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins seem to have a neutral effect; and acetylsalicylic acid could be associated with excess mortality.
%K Age ≥ 80
%K Cardiometabolic therapy
%K Coronavirus disease-2019
%K Mortality
%K Type 2 diabetes
%K Área Sanitaria Norte de Córdoba
%~